Jiang-Ping Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jiang-Ping Wu has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Daniel R. Goldberg
2 shared publicationsJonathan Emeigh
Department of Medicinal Chemistry, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Road, Ridgefield, Connecticut 06877
2 shared publicationsAndre White
1 shared publicationAsitha Abeywardane
1 shared publicationBrian Werneburg
1 shared publicationCharline Peng
Research and Development, Boehringer Ingelheim Pharmaceuticals, 900 Ridgebury Road, Ridgefield, Connecticut 06877
1 shared publication
Latest Publications
- 1 August 2007
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 17 (16) , 4664-4669
The discovery of carboline analogs as potent MAPKAP-K2 inhibitors
- 1 August 2007
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 17 (16) , 4664-4669
The discovery of carboline analogs as potent MAPKAP-K2 inhibitors
- 26 February 2005
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 7 (7) , 1223-1225
Alkylation of Magnesium Sulfinates: A Direct Transformation of Functionalized Aromatic/Heteroaromatic Halides into Sulfones
Sulfinate alkylation is one of the conventional methods for sulfone synthesis. The alkylation of magnesium sulfinates, which are easily accessible via reactions of organomagnesium intermediates with sulfur dioxide, provides a convenient route for sulfone preparation. In this communication, we report a preliminary study of the alkylation of arylmagnesium sulfinates. An application of this reaction to directly transform functionalized aromatic/heteroaromatic halides into sulfones is also described.
- 26 February 2005
- Published by American Chemical Society (ACS) in Organic Letters
- Vol. 7 (7) , 1223-1225
Alkylation of Magnesium Sulfinates: A Direct Transformation of Functionalized Aromatic/Heteroaromatic Halides into Sulfones
Sulfinate alkylation is one of the conventional methods for sulfone synthesis. The alkylation of magnesium sulfinates, which are easily accessible via reactions of organomagnesium intermediates with sulfur dioxide, provides a convenient route for sulfone preparation. In this communication, we report a preliminary study of the alkylation of arylmagnesium sulfinates. An application of this reaction to directly transform functionalized aromatic/heteroaromatic halides into sulfones is also described.
- 29 September 2004
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 47 (22) , 5356-5366
Second-Generation Lymphocyte Function-Associated Antigen-1 Inhibitors: 1H-Imidazo[1,2-α]imidazol-2-one Derivatives
A novel class of lymphocyte function-associated antigen-1 (LFA-1) inhibitors is described. Discovered during the process to improve the physicochemical and metabolic properties of BIRT377 (1, Figure 1), a previously reported hydantoin-based LFA-1 inhibitor, these compounds are characterized by an imidazole-based 5,5-bicyclic scaffold, the 1,3,3-trisubstituted 1H-imidazo[1,2-α]imidazol-2-one (i.e. structure 3). The structure−activity relationship (SAR) shows that electron−withdrawing groups at C5 on the imidazole ring benefit potency and that oxygen-containing functional groups attached to a C5-sulfonyl or sulfonamide group further improve potency. This latter gain in potency is attributed to the interaction(s) of the functionalized sulfonyl/sulfonamide groups with the protein, likely polar−polar in nature, as suggested by SAR data. X-ray studies revealed that these bicyclic inhibitors bind to the I-domain of LFA-1 in a pattern similar to that of compound 1.
- 29 September 2004
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 47 (22) , 5356-5366
Second-Generation Lymphocyte Function-Associated Antigen-1 Inhibitors: 1H-Imidazo[1,2-α]imidazol-2-one Derivatives
A novel class of lymphocyte function-associated antigen-1 (LFA-1) inhibitors is described. Discovered during the process to improve the physicochemical and metabolic properties of BIRT377 (1, Figure 1), a previously reported hydantoin-based LFA-1 inhibitor, these compounds are characterized by an imidazole-based 5,5-bicyclic scaffold, the 1,3,3-trisubstituted 1H-imidazo[1,2-α]imidazol-2-one (i.e. structure 3). The structure−activity relationship (SAR) shows that electron−withdrawing groups at C5 on the imidazole ring benefit potency and that oxygen-containing functional groups attached to a C5-sulfonyl or sulfonamide group further improve potency. This latter gain in potency is attributed to the interaction(s) of the functionalized sulfonyl/sulfonamide groups with the protein, likely polar−polar in nature, as suggested by SAR data. X-ray studies revealed that these bicyclic inhibitors bind to the I-domain of LFA-1 in a pattern similar to that of compound 1.